These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32992469)

  • 21. Successful development of oral SEDDS: screening of excipients from the industrial point of view.
    Nardin I; Köllner S
    Adv Drug Deliv Rev; 2019 Mar; 142():128-140. PubMed ID: 30414496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Stabilizing Excipients in Dry State Therapeutic Phage Formulations.
    Zhang Y; Zhang H; Ghosh D
    AAPS PharmSciTech; 2020 May; 21(4):133. PubMed ID: 32415395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
    Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
    Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir.
    Bastiaans DET; Immohr LI; Zeinstra GG; Strik-Albers R; Pein-Hackelbusch M; van der Flier M; de Haan AFJ; Boelens JJ; Lankester AC; Burger DM; Warris A
    Br J Clin Pharmacol; 2017 Dec; 83(12):2789-2797. PubMed ID: 28800385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine.
    O'Brien F; Clapham D; Krysiak K; Batchelor H; Field P; Caivano G; Pertile M; Nunn A; Tuleu C
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31159216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosin: a naturally derived excipient in drug delivery systems.
    Kumar S; Gupta SK
    Polim Med; 2013; 43(1):45-8. PubMed ID: 23808195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of taste-masking effects of pharmaceutical sweeteners with an electronic tongue system.
    Choi du H; Kim NA; Nam TS; Lee S; Jeong SH
    Drug Dev Ind Pharm; 2014 Mar; 40(3):308-17. PubMed ID: 23786206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.
    Martir J; Flanagan T; Mann J; Fotaki N
    AAPS PharmSciTech; 2020 Oct; 21(7):287. PubMed ID: 33063245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review on parenteral delivery of peptides and proteins.
    Jain D; Mahammad SS; Singh PP; Kodipyaka R
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1403-1420. PubMed ID: 31215293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate.
    Lopalco A; Curci A; Lopedota A; Cutrignelli A; Laquintana V; Franco M; Denora N
    Eur J Pharm Sci; 2019 Jan; 127():339-350. PubMed ID: 30447284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary peptide delivery: effect of taste-masking excipients on leuprolide suspension metered-dose inhalers.
    Zheng JY; Fulu MY; Lee DY; Barber TE; Adjei AL
    Pharm Dev Technol; 2001 Nov; 6(4):521-30. PubMed ID: 11775953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient centric formulations for paediatrics and geriatrics: Similarities and differences.
    Hanning SM; Lopez FL; Wong IC; Ernest TB; Tuleu C; Orlu Gul M
    Int J Pharm; 2016 Oct; 512(2):355-359. PubMed ID: 26976504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms.
    Arima H; Higashi T; Motoyama K
    Ther Deliv; 2012 May; 3(5):633-44. PubMed ID: 22834407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential aspects of chitosan as pharmaceutical excipient.
    Ray SD
    Acta Pol Pharm; 2011; 68(5):619-22. PubMed ID: 21928704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biopharmaceutical formulations for pre-filled delivery devices.
    Jezek J; Darton NJ; Derham BK; Royle N; Simpson I
    Expert Opin Drug Deliv; 2013 Jun; 10(6):811-28. PubMed ID: 23506207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and pharmacokinetic evaluation of alginate-pectin polymeric rafts forming tablets using box behnken design.
    Abbas G; Hanif M
    Drug Dev Ind Pharm; 2018 Dec; 44(12):2026-2037. PubMed ID: 30084289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multivariate analysis as a method to understand variability in a complex excipient, and its contribution to formulation performance.
    Tobyn M; Ferreira AP; Lightfoot J; Martin EB; Ghimire M; Vesey C; Kasuboski-Freeman A; Rajabi-Siahboomi A
    Pharm Dev Technol; 2018 Dec; 23(10):1146-1155. PubMed ID: 30303433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of hydrophobic peptides for skin delivery via coated microneedles.
    Zhao X; Coulman SA; Hanna SJ; Wong FS; Dayan CM; Birchall JC
    J Control Release; 2017 Nov; 265():2-13. PubMed ID: 28286315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.